Anti-LAG-3 抗体 [11E3] (ab40465)
Key features and details
- Mouse monoclonal [11E3] to LAG-3
- Suitable for: ELISA, IP, IHC-Fr, ICC/IF, Flow Cyt, Blocking, IHC-P, WB
- Reacts with: Human, Monkey
- Isotype: IgG1
製品の概要
-
製品名
Anti-LAG-3 antibody [11E3]
LAG-3 一次抗体 製品一覧 -
製品の詳細
Mouse monoclonal [11E3] to LAG-3 -
由来種
Mouse -
特異性
Recognizes the first N-terminal D1 domain of LAG-3.
-
アプリケーション
適用あり: ELISA, IP, IHC-Fr, ICC/IF, Flow Cyt, Blocking, IHC-P, WBmore details -
種交差性
交差種: Human, Monkey -
免疫原
Recombinant full length protein corresponding to Human LAG-3. (soluble form)
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
Preservative: 0.02% Sodium azide
Constituents: PBS, 10% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
精製度
Protein A purified -
特記事項(精製)
Purified from concentrated hybridoma tissue culture supernatant by Protein A Sepharose CL-4B Flow Fast Column. Purity >95% (SDS-PAGE). -
ポリ/モノ
モノクローナル -
クローン名
11E3 -
アイソタイプ
IgG1 -
研究分野
関連製品
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab40465の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
IP |
Use at an assay dependent concentration.
|
|
IHC-Fr |
Use at an assay dependent concentration.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
|
Flow Cyt |
Use 1µg for 106 cells.
|
|
Blocking |
Use at an assay dependent concentration.
|
|
IHC-P | (2) |
Use at an assay dependent concentration.
|
WB |
Use at an assay dependent concentration.
|
特記事項 |
---|
ELISA
Use at an assay dependent concentration. |
IP
Use at an assay dependent concentration. |
IHC-Fr
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
Flow Cyt
Use 1µg for 106 cells. |
Blocking
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
ターゲット情報
-
機能
Involved in lymphocyte activation. Binds to HLA class-II antigens. -
組織特異性
On cell surface of activated NK and T-lymphocytes. -
配列類似性
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 3902 Human
- Omim: 153337 Human
- SwissProt: P18627 Human
- Unigene: 409523 Human
-
別名
- CD223 antibody
- CD223 antigen antibody
- FDC protein antibody
see all
画像
-
Overlay histogram showing Jurkat cells stained with ab40465 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab40465, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (8)
ab40465 は 8 報の論文で使用されています。
- Tcvetkov N et al. Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome. Leuk Res Rep 14:100215 (2020). PubMed: 32695574
- Ma C et al. Ectopic expression of LAG-3 in non-small-cell lung cancer cells and its clinical significance. J Clin Lab Anal 34:e23244 (2020). PubMed: 32077528
- Zhu P et al. MiRNA505/NET1 Axis Acts as a CD8+ T-TIL Regulator in Non-Small Cell Lung Cancer. Onco Targets Ther 13:9785-9795 (2020). PubMed: 33061457
- Lee SJ et al. LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. J Immunother 42:279-283 (2019). PubMed: 31219974
- Lee WJ et al. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes. J Am Acad Dermatol N/A:N/A (2019). PubMed: 30880064
- Wang W et al. Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma. Ann Transl Med 7:776 (2019). PubMed: 32042792
- Takada K et al. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med 16:86 (2018). IHC-P ; Human . PubMed: 29615076
- Huard B et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A 94:5744-9 (1997). PubMed: 9159144